{"id":"adebrelimab-combined-with-sox-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Myelosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adebrelimab is a monoclonal antibody targeting programmed death ligand 1 (PD-L1), which when bound to PD-1 on T cells suppresses anti-tumor immunity. By blocking this interaction, adebrelimab releases the brakes on T cell activation, allowing enhanced tumor recognition and killing. The SOX regimen provides direct chemotherapy-induced cytotoxicity, and the combination leverages both chemotherapy and immunotherapy mechanisms.","oneSentence":"Adebrelimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with SOX chemotherapy (S-1 and oxaliplatin) for enhanced cytotoxic and immunological effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:18:56.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer or gastroesophageal junction cancer (in combination with SOX chemotherapy)"}]},"trialDetails":[{"nctId":"NCT07314203","phase":"PHASE3","title":"Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-12-25","conditions":"Gastric Cancer, Surgery","enrollment":118},{"nctId":"NCT06192186","phase":"PHASE4","title":"Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Yang Jianjun, PhD","startDate":"2023-12-30","conditions":"Locally Advanced Gastric Adenocarcinoma","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Adebrelimab combined with SOX regimen","genericName":"Adebrelimab combined with SOX regimen","companyName":"Yang Jianjun, PhD","companyId":"yang-jianjun-phd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adebrelimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with SOX chemotherapy (S-1 and oxaliplatin) for enhanced cytotoxic and immunological effects. Used for Gastric cancer or gastroesophageal junction cancer (in combination with SOX chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}